Hikma Pharmaceuticals’ (HIK) “Equal Weight” Rating Reaffirmed at Barclays

Barclays reissued their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has a GBX 2,000 ($25.13) price target on the stock.

Separately, Berenberg Bank reissued a hold rating and issued a GBX 2,000 ($25.13) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of GBX 2,068.75 ($25.99).

Hikma Pharmaceuticals Price Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,981 ($24.89) on Tuesday. The firm has a market cap of £4.40 billion, a PE ratio of 2,913.24, a price-to-earnings-growth ratio of 2.38 and a beta of 0.44. The company’s fifty day simple moving average is GBX 1,878.02 and its two-hundred day simple moving average is GBX 1,863.84. The company has a quick ratio of 1.27, a current ratio of 1.57 and a debt-to-equity ratio of 53.92. Hikma Pharmaceuticals has a 12-month low of GBX 1,711 ($21.49) and a 12-month high of GBX 2,222 ($27.91).

Hikma Pharmaceuticals Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st were given a dividend of $0.47 per share. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. The ex-dividend date was Thursday, March 21st. Hikma Pharmaceuticals’s payout ratio is presently 8,382.35%.

Insiders Place Their Bets

In related news, insider Riad Mishlawi bought 736 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were purchased at an average price of GBX 1,979 ($24.86) per share, with a total value of £14,565.44 ($18,298.29). Company insiders own 30.74% of the company’s stock.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.